Pharmaceutical Los Angeles, USA-based Abraxis BioScience saw its shares leap 30% to $52 in flat Nasdaq market trading yesterday, after the company announced that its randomized registrational Phase III clinical trial comparing Abraxane (protein-bound paclitaxel) with Bristol-Myers Squibb's Taxol (paclitaxel) injection, both in combination with carboplatin, met the study's primary endpoint, demonstrating that Abraxane showed a significant improvement in overall response rate as compared to Taxol, in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC), as assessed by independent radiologist review. 18 March 2010